Impact of Hemodialysis Therapy on Anemia of Chronic Kidney Disease: The Potential Mechanisms

被引：38

作者：

Bowry, Sudhir K. ^{[1
]}

Gatti, Emanuele ^{[2
]}

机构：

[1] Fresenius Med Care, Sci Affairs, DE-61352 Bad Homburg, Germany

[2] Univ Krems, Ctr Biomed Technol Danube, Krems, Austria

来源：

BLOOD PURIFICATION | 2011年 / 32卷 / 03期

关键词：

Online hemodiafiltration; Anemia of chronic kidney disease; Uremic toxins; PATIENTS RECEIVING HEMODIAFILTRATION; ONLINE HEMODIAFILTRATION; ERYTHROPOIETIN RESISTANCE; CHRONIC INFLAMMATION; ULTRAPURE DIALYSATE; INTRAVENOUS IRON; MORTALITY RISK; CFU-E; HEMOGLOBIN; MANAGEMENT;

D O I：

10.1159/000329573

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

A significant and increasing number of chronic kidney disease (CKD) patients are treated with online hemodiafiltration (OL-HDF), even in the absence of more conclusive survival data. OL-HDF affords several clinical benefits including control of anemia of CKD, a common affliction in dialysis patients. In efforts to understand the underlying mechanisms that contribute to the purported benefits of OL-HDF, we examined the potential role and impact of OL-HDF on key stages of anemia and its correction: erythropoiesis of bone marrow, circulating erythrocytes and on anemia therapy. We review evidence that indicates OL-HDF may modulate key processes of anemia and its therapy, including underlying conditions and responses of uremic toxicity and inflammation that aggravate anemia. Our assessment indicates that OL-HDF favorably impacts anemia by not only eliminating putative uremic inhibitors that suppress erythropoiesis, reducing red cell destruction and increasing iron availability, but also by mechanisms restricting underlying inflammation and endothelial dysfunction that are crucial to both CKD and anemia. Copyright (C) 2011 S. Karger AG, Basel

引用

页码：210 / 219

页数：10

共 74 条

[1]

Allen DA, 1999, J INVEST MED, V47, P204

[2]

The General Picture of Uremia [J].

Almeras, Cyrielle ;

Argiles, Angel .

SEMINARS IN DIALYSIS, 2009, 22 (04) :329-333

[3]

[Anonymous], 2002, NEPHROL DIAL TRAN S7, V17, P45

[4]

Ayli D, 2004, J NEPHROL, V17, P701

[5]

Molecular Mechanisms of Hepcidin Regulation: Implications for the Anemia of CKD [J].

Babitt, Jodie L. ;

Lin, Herbert Y. .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 55 (04) :726-741

[6]

Improvement of anemia in hemodialysis patients treated by hemodiafiltration with high-volume on-line-prepared substitution fluid [J].

Bonforte, G ;

Grillo, P ;

Zerbi, S ;

Surian, M .

BLOOD PURIFICATION, 2002, 20 (04) :357-363

[7]

Removal of uraemic plasma factor(s) using different dialysis modalities reduces phosphatidylserine exposure in red blood cells [J].

Bonomini, M ;

Ballone, E ;

Di Stante, S ;

Bucciarelli, T ;

Dottori, S ;

Arduini, A ;

Urbani, A ;

Sirolli, V .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (01) :68-74

[8]

Bonomini M, 2003, J NEPHROL, V16, P21

[9]

Bowry SK, 2005, CONTRIB NEPHROL, V149, P230, DOI 10.1159/000085685

[10]

Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS [J].

Canaud, B. ;

Bragg-Gresham, J. L. ;

Marshall, M. R. ;

Desmeules, S. ;

Gillespie, B. W. ;

Depner, T. ;

Klassen, P. ;

Port, F. K. .

KIDNEY INTERNATIONAL, 2006, 69 (11) :2087-2093

← 1 2 3 4 5 6 7 8 →